News Release: July 26, 2025
Medical Grade Activated Carbon Price Trend in Past Five Years and Factors Impacting Price Movements (2019–2024)
Over the past five years, the Medical Grade Activated Carbon price trend has undergone considerable fluctuations due to a range of global and regional market factors, including raw material availability, manufacturing capacities, regulatory changes, supply chain disruptions, and end-user industry demand.
In 2019, the average price of Medical Grade Activated Carbon stood at approximately $2,200/MT. This pricing was mainly stable due to consistent global demand from the pharmaceutical and medical device industries, particularly in North America and Europe. The production levels were moderate, and there was little disruption to supply chains.
In 2020, during the onset of the COVID-19 pandemic, the price rose slightly to $2,350/MT due to increased demand in medical applications such as blood purification and respiratory treatment devices. However, this increase was tempered by supply chain issues and temporary halts in production in major manufacturing hubs like China and India.
By 2021, supply chains had gradually normalized, but increased freight costs and logistics challenges drove prices up further. The average Medical Grade Activated Carbon price climbed to $2,500/MT. Additionally, the rising cost of raw materials like coconut shells, coal, and wood-based sources contributed to the upward price movement.
In 2022, the price experienced a sharp rise to around $2,850/MT. The key factors were soaring energy prices, supply chain congestion, and increasing demand from the expanding medical infrastructure in developing nations. Major producers struggled to keep pace with the rising sales volume, especially as new applications in medical detoxification and advanced drug delivery emerged.
2023 saw some correction in pricing due to an increase in global Medical Grade Activated Carbon production capacity. Prices slightly dipped to an average of $2,650/MT as major players in China, the US, and Southeast Asia expanded operations and improved efficiency. However, stringent environmental regulations in Europe and the US for activated carbon production added to the production cost.
In early 2024, prices started stabilizing around $2,700/MT, indicating a maturing market. However, the industry still faced pressure from fluctuating raw material prices and new safety standards for medical-grade products, which impacted the cost structure.
By tracking the Medical Grade Activated Carbon price trend and production news, stakeholders can understand the dynamic factors affecting this market. The complete breakdown of this trend is available here:
Medical Grade Activated Carbon price trend and production News
Medical Grade Activated Carbon Price Trend Quarterly Update in $/MT (2025)
- Q1 2025: $2,750/MT
- Q2 2025: $2,800/MT
- Q3 2025: $2,790/MT
- Q4 2025: $2,820/MT
In 2025, the Medical Grade Activated Carbon price trend is showing a gradual and steady increase across all quarters. The Q1 price of $2,750/MT reflected strong start-of-year demand from pharmaceutical sectors, with slight bottlenecks in transportation due to seasonal delays. In Q2, increased procurement by medical consumables manufacturers pushed prices to $2,800/MT.
In Q3, despite a slight reduction in production costs due to improved automation in manufacturing, prices remained firm at $2,790/MT. This was supported by sustained demand from Europe and South America. Q4 saw a small uptick to $2,820/MT owing to bulk procurement ahead of the year-end shutdowns in major production hubs.
Global Medical Grade Activated Carbon Import-Export Business Overview (2025)
The global import-export business for Medical Grade Activated Carbon in 2025 is experiencing a dynamic shift as both production capabilities and demand centers continue to evolve. Key exporting countries include China, the United States, India, and Sri Lanka, while major importing nations are Japan, Germany, France, the United Kingdom, Brazil, and several Gulf countries.
China remains the world’s largest exporter of Medical Grade Activated Carbon, contributing over 35% of the global exports. In 2025, the country expanded its production capacity by 8%, enabling it to increase its export volume significantly. China’s competitive pricing, coupled with investment in automated and environmentally compliant manufacturing plants, has made its exports more attractive to European and Middle Eastern countries.
India’s Medical Grade Activated Carbon production has also surged, with new factories coming online in southern and western regions. The country’s exports have grown by approximately 12% year-on-year, driven by increased demand from Southeast Asian and African nations. The Indian market emphasizes coconut shell-based activated carbon, which is preferred for its purity and high absorption capacity.
In contrast, the United States primarily exports premium-grade Medical Grade Activated Carbon with specific applications in high-end pharmaceutical products and critical care medical devices. In 2025, US exports focused heavily on Canada, Mexico, and parts of Western Europe. Despite higher production costs, US exporters have maintained their market share by offering FDA-compliant products with detailed quality certification.
On the import side, Japan remains the largest Asian importer, with an annual import volume of around 7,000 MT. Its imports mainly support its domestic pharmaceutical industry, which requires strict compliance with medical quality standards. Germany and France are the largest European importers, each bringing in approximately 5,000–6,000 MT annually.
Brazil has emerged as a growing importer in 2025, supported by the rapid expansion of its medical infrastructure and increasing investment in public health. Brazil’s government recently introduced subsidies on critical medical materials, boosting the Medical Grade Activated Carbon sales volume domestically. Most of its imports are sourced from the US and India due to proximity and cost efficiency.
Gulf countries like the UAE and Saudi Arabia are importing increased quantities of Medical Grade Activated Carbon to support their vision of becoming regional medical hubs. The Middle East’s import demand rose by 18% compared to 2024, and is projected to grow further into 2026. The construction of new hospitals and dialysis centers is a major driver behind this demand.
In terms of pricing strategy, exporters from Asia are offering flexible shipping options and volume discounts, which is helping them penetrate smaller markets in Eastern Europe and Africa. However, rising global shipping and container costs in mid-2025 posed challenges for low-margin suppliers, pushing some toward regional trade rather than global export.
Technological developments in Medical Grade Activated Carbon production, such as steam activation with energy recovery and surface modification techniques, are further optimizing yield and reducing per-unit costs. These advancements are playing a crucial role in shaping global trade as manufacturers leverage efficiency to meet tight regulatory and safety standards in importing countries.
Moreover, trade agreements between regional blocs have significantly influenced import-export dynamics. The RCEP (Regional Comprehensive Economic Partnership) has eased trade for Asian producers, while EU’s Green Deal is pushing European importers to demand environmentally certified carbon products, impacting exporter selection.
As of mid-2025, the global Medical Grade Activated Carbon sales volume is estimated to have grown by 6.5% year-on-year. Despite geopolitical tensions in certain regions, most major trade routes have remained stable. The combination of regulatory alignment, quality assurance protocols, and innovative packaging has allowed the global import-export ecosystem to function efficiently.
In summary, the global Medical Grade Activated Carbon market in 2025 is characterized by moderate price increases, technological improvements in production, and a reshaping of trade relationships in favor of quality and sustainability. Exporters and importers alike are adapting to new market demands, stricter compliance requirements, and evolving healthcare priorities across continents.
To learn more or request a sample report, visit:
Medical Grade Activated Carbon Production Trends by Geography (2025)
Medical Grade Activated Carbon production in 2025 is shaped by regional advancements, local demand, raw material availability, and regulatory environments. Key geographies include Asia-Pacific, North America, Europe, and emerging contributors in Latin America and the Middle East. Each region has developed distinct production trends depending on infrastructure, industrial capabilities, and proximity to raw materials.
Asia-Pacific
Asia-Pacific remains the largest producer of Medical Grade Activated Carbon in 2025. China leads this region with over 40% of global production, leveraging abundant raw materials, established supply chains, and large-scale industrial facilities. Production is mainly based on coal and wood-derived activated carbon, with a gradual shift toward sustainable methods such as coconut shell activation. Major provinces like Guangdong, Jiangsu, and Shandong are key production zones, with upgraded facilities complying with international medical standards.
India follows closely, emphasizing coconut shell-based Medical Grade Activated Carbon due to high availability of raw material in southern coastal regions. Tamil Nadu and Kerala are central to India’s production landscape, hosting several high-capacity plants. These plants cater both to domestic demand and export markets across Africa, the Middle East, and Southeast Asia. Indian manufacturers have increasingly adopted steam activation technologies, reducing their environmental footprint while maintaining competitive pricing.
Indonesia, Sri Lanka, and the Philippines are also contributing steadily to global production. These countries have invested in smaller but efficient facilities that supply activated carbon with high purity, ideal for medical applications. Sri Lanka’s exports are primarily focused on Europe and North America, given the high quality of their coconut shell carbon.
North America
The United States is a major producer of premium-quality Medical Grade Activated Carbon. Production facilities in Texas, California, and Pennsylvania are focused on high-end applications in dialysis, wound care, and pharmaceutical formulations. US production prioritizes stringent quality control, with an emphasis on regulatory compliance with FDA and USP standards. Activated carbon derived from wood and bituminous coal is most common in US production facilities.
In 2025, the US government continues to support domestic production through tax incentives and research funding aimed at enhancing carbon treatment processes and sustainability. This has led to new facilities being equipped with advanced chemical activation systems that ensure high purity and consistency in particle size.
Canada produces a modest share but plays an important role in high-spec applications. Canadian producers mainly serve domestic and US markets, with increasing interest in exports to Japan and Western Europe.
Europe
Europe’s Medical Grade Activated Carbon production is highly regulated, focusing on environmental compliance and sustainable practices. Germany, the United Kingdom, and France are key producers in the region. These countries produce activated carbon from wood and lignite, with manufacturers investing heavily in energy-efficient production lines.
Germany’s market stands out for its research-oriented production approach. Facilities in Bavaria and North Rhine-Westphalia are developing specialized carbon grades tailored for new medical technologies like wearable detoxification devices and implantable medical filters.
The United Kingdom, despite higher energy costs, remains a competitive producer due to its focus on niche applications and contract manufacturing for pharma companies. France has seen modest growth in production, supported by government initiatives to boost domestic supply for healthcare.
Middle East and Africa
Though not traditionally strong in production, some Middle Eastern countries are making targeted investments. The UAE and Saudi Arabia have announced initiatives in 2025 to develop regional manufacturing hubs focused on healthcare-related materials, including Medical Grade Activated Carbon. These efforts are in early stages but reflect a growing intent to reduce dependency on imports.
South Africa is the leading producer on the African continent, leveraging its coal reserves to manufacture activated carbon. However, the proportion dedicated to medical-grade applications remains limited due to cost and purity constraints.
Latin America
Brazil and Mexico are emerging players in Medical Grade Activated Carbon production. Brazil’s focus is primarily on meeting domestic demand, with small-scale facilities in São Paulo and Minas Gerais producing coconut shell-based carbon. Mexico, on the other hand, benefits from trade agreements with the US and Canada, allowing it to develop a manufacturing base for exports under North American standards.
Overall, the geographical distribution of Medical Grade Activated Carbon production in 2025 reflects the convergence of resource availability, regulatory pressure, and demand-side dynamics. Asia-Pacific continues to dominate in volume, North America leads in premium quality, and Europe emphasizes sustainability and compliance. Emerging regions are gradually entering the production landscape to meet growing healthcare needs worldwide.
Medical Grade Activated Carbon Market Segmentation
Market Segments:
- By Raw Material
- Coal-based
- Wood-based
- Coconut shell-based
- Others
- By Form
- Powdered Activated Carbon (PAC)
- Granular Activated Carbon (GAC)
- Extruded Activated Carbon (EAC)
- By Application
- Hemoperfusion and dialysis
- Drug purification
- Respiratory devices
- Wound care and dressings
- Diagnostic testing
- By End-User
- Hospitals and Clinics
- Pharmaceutical Companies
- Medical Device Manufacturers
- Diagnostic Laboratories
- By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Explanation of Leading Segments
In the current market landscape of 2025, certain segments of Medical Grade Activated Carbon are showing dominant growth patterns driven by healthcare needs, regulatory focus, and advancements in purification technologies.
Among raw materials, coconut shell-based activated carbon is leading the market due to its high purity, lower ash content, and renewable nature. Countries like India, Sri Lanka, and the Philippines are major contributors to this segment. Medical applications demand stringent quality parameters, and coconut shell carbon meets these requirements effectively. Additionally, the global shift toward environmentally sustainable materials further supports its dominance.
Coal-based carbon, particularly from China and South Africa, continues to hold a significant market share due to its cost efficiency and established supply chain. However, its use in high-end medical applications is limited due to higher impurity levels and challenges in achieving consistent quality. Wood-based carbon remains niche but is gaining traction in Europe and North America due to its natural origins and compatibility with sustainable production standards.
In terms of form, powdered activated carbon (PAC) leads the market due to its high surface area and rapid adsorption rate. It is widely used in dialysis treatments, toxin removal, and emergency medical procedures involving poison ingestion. PAC is also favored in pharmaceutical manufacturing for drug purification processes, where rapid mixing and adsorption are critical.
Granular activated carbon (GAC), on the other hand, is used in respiratory devices and medical air filtration systems. Its durability and reusability make it a preferred choice for devices requiring long operational life. Extruded activated carbon (EAC), which combines the benefits of powdered and granular forms, is growing in demand for specialty medical devices and compact filtration units.
By application, hemoperfusion and dialysis dominate the Medical Grade Activated Carbon market. The growing prevalence of kidney disorders, especially in aging populations, has fueled demand for high-purity carbon capable of removing toxins from blood. This segment is especially strong in developed markets like the US, Japan, and Germany.
Drug purification is another key application. Medical Grade Activated Carbon is used to remove process impurities and color from pharmaceutical products. With the rapid development of biologics and biosimilars, demand for carbon used in purification systems has surged. Respiratory devices, including carbon filters in ventilators and CPAP machines, form a growing niche due to increased respiratory issues worldwide.
In wound care, activated carbon dressings help in odor control and infection management. These dressings are commonly used for chronic wounds, diabetic ulcers, and post-surgical healing. This application has shown significant growth in both hospital settings and outpatient care.
Among end-users, pharmaceutical companies are the largest consumers, using activated carbon in both research and production environments. Hospitals and clinics represent another large segment, primarily through the use of dialysis machines, blood purification systems, and wound dressings. Medical device manufacturers are increasing their use of carbon in portable treatment and monitoring devices, particularly for homecare applications.
Geographically, Asia-Pacific leads the demand due to high population density and a growing network of healthcare infrastructure. North America shows strong demand for premium applications with tight regulatory control. Europe focuses on sustainability and imports a substantial portion of its carbon from certified suppliers.
In conclusion, the Medical Grade Activated Carbon market in 2025 is segmented along multiple lines, with certain raw materials and applications clearly taking the lead. Coconut shell-based PAC used in dialysis and pharmaceutical purification is expected to retain its leadership due to effectiveness, compliance, and sustainability. The ongoing expansion of healthcare services globally, along with innovation in medical devices, ensures continued growth across multiple market segments.